Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20220202004
TCTR20220202004
Unknown
Phase 1

Clinical and pathological response of pre-operative Intratumoral and Intramuscular Poly-ICLC(Hiltonol) for cutaneous melanoma stage 2 and 3

/A0 sites12 target enrollmentFebruary 2, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscutaneous melanoma stage 2 and 3cutaneous melanomamelanoma stage 2 and 3Hiltonolpoly-ICLCimmunotherapyneoantigentherapeutic cancer vaccine

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
cutaneous melanoma stage 2 and 3
Sponsor
/A
Enrollment
12
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 2, 2022
End Date
February 28, 2023
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
/A

Eligibility Criteria

Inclusion Criteria

  • •1\. diagnosed with cutaneous melanoma stage 2 and 3
  • •2\. age more than 18 years old
  • •3\. expected life expectancy more than 6 months
  • •4\. ECOG 0\-1
  • •5\. inform\-consent to be part of the research
  • •6\. normal liver and kidneys functions as state in the protocol

Exclusion Criteria

  • •1\. allergy to poly\-ICLC
  • •2\. melanoma at face
  • •3\. autoimmune disease
  • •4\. history of immunologic treatment except antibody treatment and discontinue the drug more than 4 weeks
  • •5\. history of CMT, RT, or targeted therapy and discontinue less than 2 weeks
  • •6\. history of others carcinoma except BCC or SCC which can be treat locally
  • •7\. HIV infection
  • •8\. receive live attenuated vaccine and killed vaccine within 28 days before receiving 1st dose of poly\-ICLC
  • •9\. prescribed with prednisolone more than 10 mg per day except inhaled or intranasal corticosteroids
  • •10\. any health issues the might interfere with the efficacy of the drug and/or harmful to one health associated with using poly\-ICLC

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Features and Outcome of Patients with preoperative Severe Hypertensioabnormal hypertension before elective surgery
JPRN-UMIN000035815Toho University1,000
Recruiting
Phase 3
Comparison between Rosemary gargle versus Lidocaine gargle on sore throat and voice violence after endotracheal intubation under general anesthesia in candidates patients for surgeries
IRCT20101211005362N29Esfahan University of Medical Sciences90
Not yet recruiting
Not Applicable
Effect of preoperative sildenafil on patients with severe pulmonary hypertension undergoing heart valve replacement.
ACTRN12611000267954Richard Renew50
Recruiting
Phase 4
Clinical outcomes and safety of preoperative non-preserved steroid eye drop in trabeculectomy: A randomised controlled trialDue to COVID&#4519 pandemic&#44the collection and other process may be delayed. Some patients visits may be postponed.Cytokines&#44glaucoma&#44inflammation&#44preoperative topical steroid&#44steroid eye drop&#44trabeculectomy
TCTR20201015003Ratchadapiseksompotch Fund162
Active, not recruiting
Not Applicable
The incidence and severity of abnormal preoperative laboratory investigations in healthy patients undergoing elective cataract surgeriesA cataract surgery is the low risk surgical procedure mostly performed on elderly patients. The surgery is usually preceded by preoperative investigation to minimize the riskbut it is questionablCost, Laboratory investigations, Preoperative cataract surgeries
TCTR20200512004one545